深静脈血栓症における新興分子標的:炎症から凝固まで

Zhuying Zhang¹, Jiaqi Hu², Yanfeng Bai¹

¹Department of Orthopedics, Jiaxing Second Hospital, Jiaxing, People's Republic of China.

Hematology (Amsterdam, Netherlands)

|September 3, 2025

まとめ

炎症は免疫血栓症を通して深静脈血栓症 (DVT) を引き起こします. 中性粒子の細胞外トラップ (NETs) やPセレクチンなどの標的分子は,抗凝固剤を超えて新しい治療法を提供することができます.

科学分野:

血管生物学
免疫学
血液学

背景:

深い静脈栓塞 (DVT) は肺栓塞のような重症な血管疾患である.
炎症は,免疫血栓形成による凝固に関連した,DVTの病原性の重要な要因としてますます認識されています.

研究の目的:

DVTにおける炎症と凝固経路を橋渡しする新興分子標的を調べる
これらの分子を新しい DVT 治療の標的として治療の可能性を探る

主な方法:

DVTにおける分子標的に関する最近の発見を集約した文献レビュー.
中性粒子の細胞外トラップ (NETs),PAD4,Pセレクチン,HMGB1,組織因子 (TF),コンプリメントC3,NLRP3炎症体に焦点を当てます.

主要な成果:

NETは,骨組みを提供し,因子XIIを活性化し,凝固を安定させることで,血栓を促進します.
PAD4,P-セレクチン,HMGB1,TF,コンプリメントC3,NLRP3炎症体は,DVTにおける炎症と凝固のクロストラックの主要な媒介体である.
臨床前データは有望ですが治療的な翻訳には種の違いや標的外効果などの課題があります

結論:

特定された分子をターゲットにすることで,出血を防ぐ DVT 治療法を開発する可能性を秘めています.
オミクスとスクリーニング技術の革新は,DVTの新たな治療目標の発見を加速させる可能性があります.

キーワード:

凝固する深静脈血栓症炎症中性粒子の細胞外トラップ

さらに関連する動画

06:44

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Published on: April 13, 2018

10.1K

04:34

Mouse Complete Stasis Model of Inferior Vena Cava Thrombosis

Published on: June 15, 2011

18.4K

関連する概念動画

01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

889

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

889

01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

01:20

Extrinsic and Intrinsic Pathways of Hemostasis

9.2K

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

9.2K

01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...